纳米药物在非肌层浸润性膀胱癌灌注治疗中的应用

喻青松; 甘志华

doi:10.11777/j.issn1000-3304.2022.22157

您当前的位置：

首页 >

文章列表页 >

纳米药物在非肌层浸润性膀胱癌灌注治疗中的应用

专论 | 更新时间：2023-05-22

- 纳米药物在非肌层浸润性膀胱癌灌注治疗中的应用
- The Application of Nanomedicine in the Intravesical Instillation Therapy of Non-muscle Invasive Bladder Cancer
- 高分子学报 2023年54卷第1期页码：1-13
- 作者机构：
  
  有机无机复合材料国家重点实验室生物医用材料(北京)实验室北京化工大学生命科学与技术学院北京 100029
- 作者简介：
  
  [ "甘志华，男，1965年生. 1987年毕业于天津大学获学士学位，1990年于天津大学获硕士学位，1993年于中国科学院长春应用化学研究所获博士学位，导师姜炳政研究员. 1993~1997年任中国科学院长春应用化学研究所副研究员. 1997~1998年在香港中文大学从事博士后研究，合作导师吴奇院士. 1998~2004年于日本理化学研究所高分子研究室担任研究员. 2004年回国加入中国科学院化学研究所工程塑料实验室，任研究员、博士生导师. 2012年加入北京化工大学生命科学与技术学院，任教授、博士生导师. 先后获得中科院百人计划、国家杰出青年基金资助，享受国务院特殊津贴. 目前主要从事生物医用与环境友好高分子材料的合成与改性研究." ]
- 基金信息：
- DOI：10.11777/j.issn1000-3304.2022.22157
  中图分类号：
- 纸质出版日期：2023-01-20，
  
  网络出版日期：2022-09-17，
  
  收稿日期：2022-04-29，
  
  录用日期：2022-06-20
扫描看全文
喻青松,甘志华.纳米药物在非肌层浸润性膀胱癌灌注治疗中的应用[J].高分子学报,2023,54(01):1-13.

Yu Qing-song,Gan Zhi-hua.The Application of Nanomedicine in the Intravesical Instillation Therapy of Non-muscle Invasive Bladder Cancer[J].ACTA POLYMERICA SINICA,2023,54(01):1-13.
喻青松,甘志华.纳米药物在非肌层浸润性膀胱癌灌注治疗中的应用[J].高分子学报,2023,54(01):1-13. DOI： 10.11777/j.issn1000-3304.2022.22157.

Yu Qing-song,Gan Zhi-hua.The Application of Nanomedicine in the Intravesical Instillation Therapy of Non-muscle Invasive Bladder Cancer[J].ACTA POLYMERICA SINICA,2023,54(01):1-13. DOI： 10.11777/j.issn1000-3304.2022.22157.

摘要

膀胱癌是泌尿系统最常见的肿瘤之一，其中非肌层浸润性膀胱癌(NMIBC)占比高达75%以上. 鉴于单纯手术治疗后好复发、易进展的特点，多个指南均推荐手术切除结合术后灌注治疗作为其标准治疗方案. 化疗作为膀胱灌注治疗的主要手段，对NMIBC治疗具有重要意义. 然而，尿液稀释、膀胱排空以及药物直接暴露等多重因素限制，极大地制约了小分子化疗药物在膀胱灌注治疗中的应用. 为改善治疗过程的安全性和疗效，多种新型给药装置或技术相继被应用于NMIBC灌注治疗，但仍难以解决毒副作用难题. 随着纳米技术的发展，其在膀胱灌注治疗中的应用逐渐受到重视，为灌注治疗过程的安全性改善带来机遇. 本文简要总结了目前NMIBC临床治疗或临床研究中的用药方案及新兴给药技术，并对临床NMIBC灌注治疗中所使用的纳米递送技术进行了归纳. 进一步结合作者和国内外同行在膀胱灌注化疗纳米药物研究方面所开展的系列研究工作，对本领域的最新研究进展进行了总结，最后对膀胱灌注治疗纳米药物的发展趋势做出展望.

Abstract

Bladder cancer is one of the most common tumors of the urinary system

among which non-muscle invasive bladder cancer (NMIBC) accounts for more than 75%. Given that NMIBC is prone to recurrence and progression after surgical treatment alone

multiple guidelines recommend surgical resection combined with postoperative perfusion therapy as its standard treatment. As a common drug type for intravesical instillation therapy

chemotherapeutics plays important roles in the treatment of NMIBC. However

due to the limitations such as urine dilution

bladder voiding

and direct drug exposure

the short bladder retention and high toxicity of small drugs greatly limit their application in intravesical instillation. In order to improve the safety and efficacy of small drugs

various new drug delivery devices or technologies have been applied in NMIBC therapy

but the problem of side effects of instillation therapy still cannot be solved. Nanotechnologies have also attracted substantial research interest due to their capacity to improve the safety and effectiveness of the instillation therapy. This article briefly summarizes the current new drugs and drug delivery technologies in clinical treatments of NMIBC. Along with the progresses made by themselves and some other research groups

the authors summarize the recent progresses of nanomedicines used in intravesical instillation therapy and make an outlook on the future prospects of such kind of nanomedicines.

关键词

癌症治疗非肌层浸润性膀胱癌膀胱灌注治疗纳米药物

Keywords

Cancer therapyNon-muscle invasive bladder cancerIntravesical instillation chemotherapyNanomedicine

references

Zheng R, Zhang S, Zeng H, Wang S, Sun K, Chen R, Li L, Wei W, He J. Cancer incidence and mortality in China, 2016. J. Nat. Cancer Cent., 2022, 2, 1-9. doi:10.1016/j.jncc.2022.02.002http://dx.doi.org/10.1016/j.jncc.2022.02.002

郑荣寿, 孙可欣, 张思维, 曾红梅, 邹小农, 陈茹, 顾秀瑛, 魏文强, 赫捷. 2015年中国恶性肿瘤流行情况分析. 中华肿瘤杂志, 2019, 41, 19-28. doi:10.3760/cma.j.issn.0253-3766.2019.01.005http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2019.01.005

Mertens L. S.; Neuzillet Y.; Horenblas S.; van Rhijn B. W. G. Landmarks in non-muscle-invasive bladder cancer. Nat. Rev. Urol., 2014, 11, 476-480. doi:10.1038/nrurol.2014.130http://dx.doi.org/10.1038/nrurol.2014.130

Chang S. S.; Boorjian S. A.; Chou R.; Clark P. E.; Daneshmand S.; Konety B. R.; Pruthi R.; Quale D. Z.; Ritch C. R.; Seigne J. D.; Skinner E. C.; Smith N. D.; McKiernan J. M. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol., 2016, 196, 1021-1029. doi:10.1016/j.juro.2016.06.049http://dx.doi.org/10.1016/j.juro.2016.06.049

Babjuk M.; Burger M.; Compérat E. M.; Gontero P.; Mostafid H. A.; Palou J.; van Rhijn B. W. G.; Rouprêt M.; Shariat S. F.; Sylvester R.; Zigeuner R.; Capoun O.; Cohen D.; Dominguez-Escrig J. L.; Hernández V.; Peyronnet B.; Seisen T.; Soukup V. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 update. Eur. Urol. Suppl., 2019, 76, 639-657. doi:10.1016/j.eururo.2019.08.016http://dx.doi.org/10.1016/j.eururo.2019.08.016

中国肿瘤医院泌尿肿瘤协作组. 非肌层浸润性膀胱癌膀胱灌注治疗专家共识(2021版), 中华肿瘤杂志, 2021, 43, 1027-1033

Redelman-Sidi G.; Glickman M. S.; Bochner B. H. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat. Rev. Urol., 2014, 11, 153-162. doi:10.1038/nrurol.2014.15http://dx.doi.org/10.1038/nrurol.2014.15

Shore N. D.; Palou Redorta J.; Robert G.; Hutson T. E.; Cesari R.; Hariharan S.; Rodríguez Faba Ó.; Briganti A.; Steinberg G. D. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol. Oncol. Semin. Orig. Investig., 2021, 39, 642-663. doi:10.1016/j.urolonc.2021.05.015http://dx.doi.org/10.1016/j.urolonc.2021.05.015

Bree K. K.; Brooks N. A.; Kamat A. M. Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer. Oncol. Clin. N Am, 2021, 35, 513-529. doi:10.1016/j.hoc.2021.02.003http://dx.doi.org/10.1016/j.hoc.2021.02.003

Joice G. A.; Bivalacqua T. J.; Kates M. Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nat. Rev. Urol., 2019, 16, 599-612. doi:10.1038/s41585-019-0220-4http://dx.doi.org/10.1038/s41585-019-0220-4

Lammers R. J. M.; Witjes J. A.; Inman B. A.; Leibovitch I.; Laufer M.; Nativ O.; Colombo R. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur. Urol., 2011, 60, 81-93. doi:10.1016/j.eururo.2011.04.023http://dx.doi.org/10.1016/j.eururo.2011.04.023

van Valenberg F. J. P.; van der Heijden A. G.; Lammers R. J. M.; Falke J.; Arends T. J. H.; Oosterwijk E.; Witjes J. A. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int. J. Hyperth., 2018, 34, 988-993. doi:10.1080/02656736.2017.1406618http://dx.doi.org/10.1080/02656736.2017.1406618

Colombo R.; Salonia A.; Leib Z.; Pavone-Macaluso M.; Engelstein D. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int., 2011, 107, 912-918. doi:10.1111/j.1464-410x.2010.09654.xhttp://dx.doi.org/10.1111/j.1464-410x.2010.09654.x

di Stasi, S M.; Giannantoni A.; Massoud R.; Dolci S.; Navarra P.; Vespasiani G.; Stephen R. L. Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res., 1999, 59, 4912-4918.

di Stasi S. M.; Giannantoni A.; Stephen R. L.; Capelli G.; Navarra P.; Massoud R.; Vespasiani G. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J. Urol., 2003, 170, 777-782. doi:10.1097/01.ju.0000080568.91703.18http://dx.doi.org/10.1097/01.ju.0000080568.91703.18

Daneshmand S.; Pohar K. S.; Steinberg G. D.; Aron M.; Cutie C. Effect of GemRIS (gemcitabine-releasing intravesical system, TAR-200) on antitumor activity in muscle-invasive bladder cancer (MIBC). J. Clin. Oncol., 2017, 35, e16000. doi:10.1200/jco.2017.35.15_suppl.e16000http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e16000

Friedman B.; Dekel Y.; Tubaro A.; Sidi A. M.; Shalva B.; Baniel J.; Kedar D.; Colombo L.; Engelshtein D.; Fridman E.; Klein I.; Jeshurun M.; Nerotski B.; Zolotrayov D.; Malchi N.; Palou Redorta J.; Wirth G.; Leibovitch I.; Witjes F. Pd11-05 the chemoablative effect of vesigel instillation in patients with nmibc - preliminary results. J. Urol., 2016, 195, e289-e290. doi:10.1016/j.juro.2016.02.845http://dx.doi.org/10.1016/j.juro.2016.02.845

Lenis A.; Chamie K.; Friedman B.; Tubaro A.; Sidi A. M.; Kedar D.; Colombo L.; Engelstein D.; Palau J.; Wirth G.; Leibovitch I.; Fridman E.; Klein I.; Jeshurun M.; Witjes F. Pd19-10 the chemoablative effect of vesigel instillation in patients with nmibc - response rate and 1-year durability. J. Urol., 2017, 197, e368-e369. doi:10.1016/j.juro.2017.02.883http://dx.doi.org/10.1016/j.juro.2017.02.883

孙瑞, 邱娜莎, 申有青. 高分子抗肿瘤纳米药物的挑战与发展. 高分子学报, 2019, 50, 588-601. doi:10.11777/j.issn1000-3304.2019.19005http://dx.doi.org/10.11777/j.issn1000-3304.2019.19005

Hurle R.; Guazzoni G.; Colombo P.; Santoro A.; de Cobelli O.; Trapani E. D.; Nohales G.; Carlos L.; Duran-Merino R.; Lazzeri M. Oncofid-P-B: A novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: results of a prospective european multicentre study at 15 months from treatment start. Urol. Oncol. Semin. Orig. Investig., 2022, 40, 11.e9-11.e15. doi:10.1016/j.urolonc.2021.07.007http://dx.doi.org/10.1016/j.urolonc.2021.07.007

Ye L.; Letchford K.; Heller M.; Liggins R.; Guan D. C.; Kizhakkedathu J. N.; Brooks D. E.; Jackson J. K.; Burt H. M. Synthesis and characterization of carboxylic acid conjugated, hydrophobically derivatized, hyperbranched polyglycerols as nanoparticulate drug carriers for cisplatin. Biomacromolecules, 2011, 12, 145-155. doi:10.1021/bm101080phttp://dx.doi.org/10.1021/bm101080p

Huang C.; Neoh K. G.; Xu L. Q.; Kang E. T.; Chiong E. Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. Biomacromolecules, 2012, 13, 2513-2520. doi:10.1021/bm300739whttp://dx.doi.org/10.1021/bm300739w

Kates M.; Date A.; Yoshida T.; Afzal U.; Kanvinde P.; Babu T.; Sopko N. A.; Matsui H.; Hahn N. M.; McConkey D. J.; Baras A.; Hanes J.; Ensign L.; Bivalacqua T. J. Preclinical evaluation of intravesical cisplatin nanoparticles for non-muscle-invasive bladder cancer. Clin. Cancer Res., 2017, 23, 6592-6601. doi:10.1158/1078-0432.ccr-17-1082http://dx.doi.org/10.1158/1078-0432.ccr-17-1082

Tan P.; Cai H.; Wei Q.; Tang X.; Zhang Q.; Kopytynski M.; Yang, J,; Yi, Y.; Zhang, H.; Gong, Q.; Gu, Z.; Chen, R.; Luo, K. Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models. Biomaterials, 2021, 277, 121061. doi:10.1016/j.biomaterials.2021.121061http://dx.doi.org/10.1016/j.biomaterials.2021.121061

Sun P. J.; Zhou D. H.; Gan Z. H. Novel reduction-sensitive micelles for triggered intracellular drug release. J. Control. Release, 2011, 155, 96-103. doi:10.1016/j.jconrel.2010.11.005http://dx.doi.org/10.1016/j.jconrel.2010.11.005

Zhou D. H.; Zhang J.; Zhang G.; Gan Z. H. Effect of surface charge of polymeric micelles on in vitro cellular uptake. Chinese J. Polym. Sci., 2013, 31, 1299-1309. doi:10.1007/s10118-013-1332-6http://dx.doi.org/10.1007/s10118-013-1332-6

Kaldybekov D. B.; Filippov S. K.; Radulescu A.; Khutoryanskiy V. V. Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery. Eur. J. Pharm. Biopharm., 2019, 143, 24-34. doi:10.1016/j.ejpb.2019.08.007http://dx.doi.org/10.1016/j.ejpb.2019.08.007

Vila-Caballer M.; Codolo G.; Munari F.; Malfanti A.; Fassan M.; Rugge M.; Balasso A.; de Bernard M.; Salmaso S. A pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: an application for bladder cancer treatment. J. Control. Release, 2016, 238, 31-42. doi:10.1016/j.jconrel.2016.07.024http://dx.doi.org/10.1016/j.jconrel.2016.07.024

Erdogar N.; İskit A. B.; Eroglu H.; Sargon M. F.; Mungan N. A.; Bilensoy E. Cationic core-shell nanoparticles for intravesical chemotherapy in tumor-induced rat model: safety and efficacy. Int. J. Pharm., 2014, 471, 1-9. doi:10.1016/j.ijpharm.2014.05.014http://dx.doi.org/10.1016/j.ijpharm.2014.05.014

Ali M. S.; Metwally A. A.; Fahmy R. H.; Osman R. Chitosan-coated nanodiamonds: Mucoadhesive platform for intravesical delivery of doxorubicin. Carbohydr. Polym., 2020, 245, 116528. doi:10.1016/j.carbpol.2020.116528http://dx.doi.org/10.1016/j.carbpol.2020.116528

Lu S. J.; Xu L. Q.; Kang E. T.; Mahendran R.; Chiong E.; Neoh K. G. Co-delivery of peptide-modified cisplatin and doxorubicin via mucoadhesive nanocapsules for potential synergistic intravesical chemotherapy of non-muscle-invasive bladder cancer. Eur. J. Pharm. Sci., 2016, 84, 103-115. doi:10.1016/j.ejps.2016.01.013http://dx.doi.org/10.1016/j.ejps.2016.01.013

Wang B. L.; Zhang K. B.; Wang J. D.; Zhao R. B.; Zhang Q.; Kong X. D. Poly(amidoamine)-modified mesoporous silica nanoparticles as a mucoadhesive drug delivery system for potential bladder cancer therapy. Colloids Surf. B Biointerfaces, 2020, 189, 110832. doi:10.1016/j.colsurfb.2020.110832http://dx.doi.org/10.1016/j.colsurfb.2020.110832

Mugabe C.; Matsui Y.; So A. I.; Gleave M. E.; Baker J. H. E.; Minchinton A. I.; Manisali I.; Liggins R.; Brooks D. E.; Burt H. M. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer. Clin. Cancer Res., 2011, 17, 2788-2798. doi:10.1158/1078-0432.ccr-10-2981http://dx.doi.org/10.1158/1078-0432.ccr-10-2981

Guo H.; Li F. P.; Qiu H. P.; Xu W. G.; Li P. Q.; Hou Y. C.; Ding J. X.; Chen X. S. Synergistically enhanced mucoadhesive and penetrable polypeptide nanogel for efficient drug delivery to orthotopic bladder cancer. Research, 2020, 2020, 1-14. doi:10.34133/2020/8970135http://dx.doi.org/10.34133/2020/8970135

Guo H.; Xu W. G.; Chen J. J.; Yan L. S.; Ding J. X.; Hou Y. C.; Chen X. S. Positively charged polypeptide nanogel enhances mucoadhesion and penetrability of 10-hydroxycamptothecin in orthotopic bladder carcinoma. J. Control. Release, 2017, 259, 136-148. doi:10.1016/j.jconrel.2016.12.041http://dx.doi.org/10.1016/j.jconrel.2016.12.041

Guo H.; Li F. P.; Xu W. G.; Chen J. J.; Hou Y. C.; Wang C. X.; Ding J. X.; Chen X. S. Mucoadhesive cationic polypeptide nanogel with enhanced penetration for efficient intravesical chemotherapy of bladder cancer. Adv. Sci., 2018, 5, 1800004. doi:10.1002/advs.201800004http://dx.doi.org/10.1002/advs.201800004

汤朝晖, 陈学思. 聚谷氨酸接枝聚乙二醇抗肿瘤药物靶向输送系统. 高分子学报, 2019, 50, 543-552. doi:10.11777/j.issn1000-3304.2019.19036http://dx.doi.org/10.11777/j.issn1000-3304.2019.19036

Mun E. A.; Williams A. C.; Khutoryanskiy V. V. Adhesion of thiolated silica nanoparticles to urinary bladder mucosa: Effects of PEGylation, thiol content and particle size. Int. J. Pharm., 2016, 512, 32-38. doi:10.1016/j.ijpharm.2016.08.026http://dx.doi.org/10.1016/j.ijpharm.2016.08.026

Wang S.; Jin S.; Li G.; Xu M.; Deng D.; Xiao Z.; Sun H.; Zhang S.; Zhang E.; Xie L.; Li G.; Dai Y.; Liu Z.; Shu Q.; Wu S. Transmucosal delivery of self-assembling photosensitizer-nitazoxanide nanocomplexes with fluorinated chitosan for instillation-based photodynamic therapy of orthotopic bladder tumors. ACS Biomater. Sci. Eng., 2021, 7, 1485-1495. doi:10.1021/acsbiomaterials.0c01786http://dx.doi.org/10.1021/acsbiomaterials.0c01786

Li G.; Yuan S.; Deng D.; Ou T.; Li Y.; Sun R.; Lei Q.; Wang X.; Shen W.; Cheng Y.; Liu Z.; Wu S. Fluorinated polyethylenimine to enable transmucosal delivery of photosensitizer-conjugated catalase for photodynamic therapy of orthotopic bladder tumors postintravesical instillation. Adv. Funct. Mater., 2019, 29(40), 1901932. doi:10.1002/adfm.201901932http://dx.doi.org/10.1002/adfm.201901932

Li G.; Lei Q.; Wang F.; Deng D.; Wang S.; Tian L.; Shen W.; Cheng Y.; Liu Z.; Wu S. Fluorinated polymer mediated transmucosal peptide delivery for intravesical instillation therapy of bladder cancer. Small, 2019, 15, 1900936. doi:10.1002/smll.201900936http://dx.doi.org/10.1002/smll.201900936

Hortelão A. C.; Carrascosa R.; Murillo-Cremaes N.; Patiño T.; Sánchez S. Targeting 3D bladder cancer spheroids with urease-powered nanomotors. ACS Nano, 2019, 13, 429-439. doi:10.1021/acsnano.8b06610http://dx.doi.org/10.1021/acsnano.8b06610

Lin T, Yuan A, Zhao X, Lian H, Zhuang J, Chen W, Zhang Q, Liu G, Zhang S, Chen W, Cao W, Zhang C, Wu J, Hu Y, Guo H. Self-assembled tumor-targeting hyaluronic acid nanoparticles for photothermal ablation in orthotopic bladder cancer. Acta Biomater., 2017, 53, 427-438. doi:10.1016/j.actbio.2017.02.021http://dx.doi.org/10.1016/j.actbio.2017.02.021

Miao L.; Guo S. T.; Zhang J.; Kim W. Y.; Huang L. Nanoparticles with precise ratiometric Co-loading and Co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater., 2014, 24, 6601-6611. doi:10.1002/adfm.201401076http://dx.doi.org/10.1002/adfm.201401076

Apfelthaler C.; Skoll K.; Ciola R.; Gabor F.; Wirth M. A doxorubicin loaded colloidal delivery system for the intravesical therapy of non-muscle invasive bladder cancer using wheat germ agglutinin as targeter. Eur. J. Pharm. Biopharm., 2018, 130, 177-184. doi:10.1016/j.ejpb.2018.06.028http://dx.doi.org/10.1016/j.ejpb.2018.06.028

Wei Y.; Gao L.; Wang L.; Shi L.; Wei E. D.; Zhou B. T.; Zhou L.; Ge B. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy. Drug Deliv., 2017, 24, 681-691. doi:10.1080/10717544.2017.1309475http://dx.doi.org/10.1080/10717544.2017.1309475

Pan A.; Zhang H. Y.; Li Y. P.; Lin T. Y.; Wang F. L.; Lee J.; Cheng M. S.; Dall'Era M.; Li T. H.; de Vere White R.; Pan C. X.; Lam K. S. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology, 2016, 27, 425103. doi:10.1088/0957-4484/27/42/425103http://dx.doi.org/10.1088/0957-4484/27/42/425103

Zhou D. H.; Zhang G.; Gan Z. H. C(RGDfK) decorated micellar drug delivery system for intravesical instilled chemotherapy of superficial bladder cancer. J. Control. Release, 2013, 169, 204-210. doi:10.1016/j.jconrel.2013.01.025http://dx.doi.org/10.1016/j.jconrel.2013.01.025

Liu H. X.; Mei C. M.; Deng X. R.; Lin W. Q.; He L. Z.; Chen T. F. Rapid visualizing and pathological grading of bladder tumor tissues by simple nanodiagnostics. Biomaterials, 2021, 264, 120434. doi:10.1016/j.biomaterials.2020.120434http://dx.doi.org/10.1016/j.biomaterials.2020.120434

Yu Q. S.; Zhang J. J.; Zhang G.; Gan Z. H. Synthesis and functions of well-defined polymer-drug conjugates as efficient nanocarriers for intravesical chemotherapy of bladder cancera. Macromol. Biosci., 2015, 15, 509-520. doi:10.1002/mabi.201400416http://dx.doi.org/10.1002/mabi.201400416

Zhou D. H.; Zhang G.; Yu Q. S.; Gan Z. H. Folic acid modified polymeric micelles for intravesical instilled chemotherapy. Chinese J. Polym. Sci., 2018, 36, 479-487. doi:10.1007/s10118-018-2009-yhttp://dx.doi.org/10.1007/s10118-018-2009-y

Lv S. W.; Jing R.; Liu X. W.; Shi H. L.; Shi Y. F.; Wang X. G.; Zhao X. B.; Cao K.; Lv Z. One-step microfluidic fabrication of multi-responsive liposomes for targeted delivery of doxorubicin synergism with photothermal effect. Int. J. Nanomed., 2021, 16, 7759-7772. doi:10.2147/ijn.s329621http://dx.doi.org/10.2147/ijn.s329621

徐鑫, 国林义, 徐涛, 喻青松, 甘志华, 张冠. 高分子纳米载药体系膀胱灌注治疗在原位膀胱癌动物模型中的初步应用. 临床泌尿外科杂志, 2019, 34, 895-900.

Xu X.; Liu K. P.; Jiao B. B.; Luo K. J.; Ren J.; Zhang G.; Yu Q. S.; Gan Z. H. Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer. J. Control. Release, 2020, 324, 493-504. doi:10.1016/j.jconrel.2020.03.028http://dx.doi.org/10.1016/j.jconrel.2020.03.028

Jiao B. B.; Liu K. P.; Gong H. T.; Ding Z. S.; Xu X.; Ren J.; Zhang G.; Yu Q. S.; Gan Z. H. Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles. J. Control. Release, 2022, 347, 632-648. doi:10.1016/j.jconrel.2022.05.031http://dx.doi.org/10.1016/j.jconrel.2022.05.031

更多指标>

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

酶响应的树枝状大分子键合物在体外肿瘤模型中的渗透行为研究

简便高效的超分子多肽治疗策略

聚谷氨酸接枝聚乙二醇抗肿瘤药物靶向输送系统

高分子抗肿瘤纳米药物的挑战与发展